Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph W Chow

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
International Journal of Antimicrobial Agents|April 2, 2017
A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in AsiaXinyu Qin, Binh Giang Tran, Min Ja Kim, et al.
The Journal of Antimicrobial Chemotherapy|May 24, 2006
In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends)Flávia Rossi, Fernando Baquero, Po-Ren Hsueh, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 13, 2002
Association between the presence of enterococcal virulence factors gelatinase, hemolysin, and enterococcal surface protein and mortality among patients with bacteremia due to Enterococcus faecalisEmanuel N Vergis, Nathan Shankar, Joseph W Chow, et al.
Surgical Infections|January 20, 2007
In vitro susceptibilities of Escherichia coli isolated from patients with intra-abdominal infections worldwide in 2002-2004: results from SMART (Study for Monitoring Antimicrobial Resistance Trends)Grant V Bochicchio, Fernando Baquero, Po-Ren Hsueh, et al.
Diagnostic Microbiology and Infectious Disease|May 19, 2007
Bowel colonization with vancomycin-resistant enterococci after antimicrobial therapy for intra-abdominal infections: observations from 2 randomized comparative clinical trials of ertapenem therapyMark J DiNubile, Ian R Friedland, Christina Y Chan, et al.
Surgical Infections|October 4, 2008
In vitro susceptibilities of aerobic and facultatively anaerobic gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2005 results from Study for Monitoring Antimicrobial Resistance Trends (SMART)Fernando Baquero, Po-Ren Hsueh, David L Paterson, et al.
The Journal of Antimicrobial Chemotherapy|April 26, 2005
In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART)David L Paterson, Flávia Rossi, Fernando Baquero, et al.
The Pediatric Infectious Disease Journal|September 26, 2009
Safety experience with caspofungin in pediatric patientsTheoklis Zaoutis, Thomas Lehrnbecher, Andreas H Groll, et al.
Antimicrobial Agents and Chemotherapy|December 17, 2008
Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of ageXavier Sáez-Llorens, Mercedes Macias, Padmanabha Maiya, et al.
The Pediatric Infectious Disease Journal|May 1, 2010
A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropeniaJohan A Maertens, Luis Madero, Anne F Reilly, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
International Journal of Antimicrobial Agents|April 2, 2017
A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in AsiaXinyu Qin, Binh Giang Tran, Min Ja Kim, et al.
The Journal of Antimicrobial Chemotherapy|May 24, 2006
In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends)Flávia Rossi, Fernando Baquero, Po-Ren Hsueh, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 13, 2002
Association between the presence of enterococcal virulence factors gelatinase, hemolysin, and enterococcal surface protein and mortality among patients with bacteremia due to Enterococcus faecalisEmanuel N Vergis, Nathan Shankar, Joseph W Chow, et al.
Surgical Infections|January 20, 2007
In vitro susceptibilities of Escherichia coli isolated from patients with intra-abdominal infections worldwide in 2002-2004: results from SMART (Study for Monitoring Antimicrobial Resistance Trends)Grant V Bochicchio, Fernando Baquero, Po-Ren Hsueh, et al.
Diagnostic Microbiology and Infectious Disease|May 19, 2007
Bowel colonization with vancomycin-resistant enterococci after antimicrobial therapy for intra-abdominal infections: observations from 2 randomized comparative clinical trials of ertapenem therapyMark J DiNubile, Ian R Friedland, Christina Y Chan, et al.
Surgical Infections|October 4, 2008
In vitro susceptibilities of aerobic and facultatively anaerobic gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2005 results from Study for Monitoring Antimicrobial Resistance Trends (SMART)Fernando Baquero, Po-Ren Hsueh, David L Paterson, et al.
The Journal of Antimicrobial Chemotherapy|April 26, 2005
In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART)David L Paterson, Flávia Rossi, Fernando Baquero, et al.
The Pediatric Infectious Disease Journal|September 26, 2009
Safety experience with caspofungin in pediatric patientsTheoklis Zaoutis, Thomas Lehrnbecher, Andreas H Groll, et al.
Antimicrobial Agents and Chemotherapy|December 17, 2008
Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of ageXavier Sáez-Llorens, Mercedes Macias, Padmanabha Maiya, et al.
The Pediatric Infectious Disease Journal|May 1, 2010
A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropeniaJohan A Maertens, Luis Madero, Anne F Reilly, et al.
Pageof 4